Instrument Inactif

Communiqués IntelGenx Technologies Corp. OTC Bulletin Board

Actions

IGX

US45822R1014

Produits pharmaceutiques

Cours en clôture OTC Bulletin Board
- ^CAD	-

07/10/24	IntelGenx Technologies Corp. annonce la démission de membres de son conseil d'administration	CI
07/10/24	IntelGenx Technologies Corp. annonce la démission de Dwight Gorham en tant que directeur général	CI

Communiqués

19/07/24	IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process	GL
03/07/24	IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease	GL
11/06/24	IntelGenx Announces Initiation of the Sale and Investment Solicitation Process	GL
28/05/24	IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process	GL
17/05/24	IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	GL
17/05/24	IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives	GL
17/05/24	Canadian Investment Regulatory Organization Trading Halt - IGX	AQ
15/05/24	IntelGenx: Q1 Earnings Snapshot	AQ
08/05/24	IntelGenx Announces Voting Results on Election of Directors	GL
08/04/24	IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	GL
08/04/24	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	AQ
05/04/24	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	GL
21/03/24	IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	GL
15/03/24	IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	PU
15/03/24	IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	PU
14/03/24	IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	GL
11/03/24	IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	AQ
11/03/24	IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	GL
20/02/24	UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	GL
05/02/24	Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	AQ
05/02/24	Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	GL
18/12/23	IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®	GL
18/12/23	IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®	AQ
05/12/23	IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000	AQ
05/12/23	IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000	GL